PPG Industries, Inc. vs Sana Biotechnology Inc — how do they compare? PPG Industries, Inc. trades at $117.3 (market cap $25.79B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: PPG Industries, Inc. is far larger — about 29.3× Sana Biotechnology Inc's market cap, and PPG Industries, Inc. pays a 2.56% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PPG | SANA | |
|---|---|---|
Market Cap | $25.79B | $879.40M |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $5.92 |
52-Week Low | $94.34 | $2.68 |
Enterprise Value | $31.90B | $853.59M |
Dividend Yield | 2.56% | — |
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $115.71, down 1.41% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 results with $15.88B revenue and $1.58B net income, and recently raised its dividend to $0.74 per share, reflecting confidence in cash flow. Analyst consensus is bullish with a $132.20 price target, though Q2 2026 earnings due July 28 are key for near-term direction.
The outlook is positive given solid profitability and dividend growth, but risks include economic sensitivity and debt levels. Upside potential exists if Q2 earnings beat expectations, while a miss could pressure the stock. The current valuation at a P/E of 16.58 appears reasonable relative to historical performance.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →